FIELD: pharmaceuticals.
SUBSTANCE: invention relates to use of the indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione N-glycoside derivative – N-{12-(β-D-xylopyranosyl)-5,7-dioxo-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl}pyridine-2-carboxamide as a compound having antitumor activity for the treatment of mice with adenocarcinoma of the mammary gland Ca 755, epidermoid carcinoma of Lewis lungs, melanoma B16, cervical cancer, adenocarcinoma of the colon ACTOL, Ehrlich tumor in therapeutic doses.
EFFECT: new application of a known biologically active compound has been proposed.
1 cl, 3 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
N-GLYCOSIDES OF INDOLO[2,3-a]PYRROLO[3,4-c]CARBAZOLES HAVING ANTITUMOUR ACTIVITY | 2014 |
|
RU2548045C1 |
TUMOUR THERAPY AGENT | 2019 |
|
RU2726801C1 |
METHOD OF PRODUCING INDOLO[2,3]PYRROLO[3,4-c]CARBAZOLE-5,7-DIONES N-GLYCOSIDES EXHIBITING CYTOTOXIC AND ANTICANCER ACTIVITY | 2009 |
|
RU2427585C9 |
DERIVATIVES OF GLYCOSIDES OF INDOLO[2,3-A]-PYRROLO[3,4-C]CARBAZOL-5,7-DIONES ELICITING CYTOTOXIC AND ANTITUMOR ACTIVITY | 2003 |
|
RU2255089C1 |
ANTI-CANCER DRUG TOPOISOMERASE I INHIBITOR | 2022 |
|
RU2786727C1 |
METHOD FOR PRODUCING AMINO ACID ANALOGUES OF THE ANTITUMOUR ANTIBIOTIC REBECCAMYCIN | 2020 |
|
RU2755572C1 |
ANTITUMOUR AGENT | 2014 |
|
RU2572691C1 |
INDOLOCARBAZOLE DERIVATIVE BLOCKING TUMOUR VASCULOGENIC MIMICRY | 2014 |
|
RU2557554C1 |
METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
3-PHENYL-10H-4,5-DIHYDROPYRAZOLO[4,3-A]CARBAZOLE SHOWING ANTITUMOR AND ANTILEUKEMIC ACTIVITY | 1991 |
|
RU2007394C1 |
Authors
Dates
2018-09-25—Published
2017-09-11—Filed